Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
BETAXON vs PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Propranolol is a non-selective beta-adrenergic receptor antagonist blocking beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and renin release; hydrochlorothiazide is a thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
Propranolol hydrochloride 40-80 mg/hydrochlorothiazide 25-50 mg orally twice daily. Maximum propranolol 640 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Propranolol: 3-6 hours (terminal half-life); can increase with hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal half-life); prolonged in renal impairment.
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Propranolol: <1% excreted unchanged in urine; extensively metabolized in liver, metabolites excreted renally. Hydrochlorothiazide: ≥95% excreted unchanged in urine via renal tubular secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker